Fully-humanized single-domain antibody for neutralizing Hunipah virus and application of fully-humanized single-domain antibody
The high-affinity full-domain antibodies Nb25 and Nb25.1 were screened through phage display technology, which solved the problem of Hennipa virus lacking effective drugs and high cost of monoclonal antibodies, provided efficient and low-cost diagnostic and treatment options, and Provides new ideas for vaccine development.
Patent Information
- Application Number
- CN202310542302.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-12
- Publication Date
- 2024-11-12
AI Technical Summary
The existing Hennipa virus lacks effective specific prevention and treatment drugs, and the high molecular weight of full-length monoclonal antibody IgG leads to high production costs, limiting its widespread application in economically underdeveloped areas.
Full human single domain antibodies Nb25 and Nb25.1 that specifically bind Hennipa virus surface receptor glycoprotein G were screened through phage display technology, and bispecific antibodies, fusion proteins and conjugates were developed for diagnosis and treat Hennipa virus infection.
Full-human single-domain antibodies with high affinity, high specificity and neutralization activity were obtained, which reduced production costs, provided potential diagnosis and treatment plans for Hennipa virus, and provided new ideas for vaccine development.
Smart Images

Figure HDA0004228435390000011 
Figure HDA0004228435390000012 
Figure HDA0004228435390000013
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biotechnology, and in particular relates to the development of single-domain fully human neutralizing antibodies against henipavirus and their applications. Background Art
[0002] So far, there is no approved specific drug for the prevention and treatment of human henipavirus. Therefore, there is an urgent need to develop an effective antiviral drug to combat this emerging global threat.
[0003] Through the recombination of antibody molecule gene level, a variety of specific mouse, humanized and fully human antibodies can be obtained, which has made a breakthrough in the research of monoclonal antibodies and increasingly demonstrated its important significance and practical application prospects. The rise of phage antibody gene library technology in the late 1980s and early 1990s and the development of the entire genetic engineering antibody technology research field have made great progress in the development and research of fully human monoclonal antibodies and new structural antibodies in the world today, and have entered the stage of substantial application research and development from the basic research stage. Human or animal serum immunoglobulins containing specific antibodies have a long history of being used to prevent and treat infectious diseases. The development of fully human monoclonal antibodies has brought new hope and great prospects for the development of biological products in this field. The in vitro antiviral neutralization activity of monoclonal antibodies and their ability to protect the body against viral attacks in vivo have been proven by many experiments. For example, monoclonal antibodies against hepatitis A virus, Hantavirus, RSV virus, SARS virus, SARS-CoV2 virus, Ebola virus, etc. can protect animals from viral attacks 100% in vivo (Nat Biotechnol, 2005. 23 (9): p. 1126-1136.). Therefore, it is necessary and feasible to identify antibodies against Henipavirus for emergency prevention and treatment.
[0004] In addition, several research groups have reported fully human neutralizing antibodies against SARS-CoV, MERS-CoV and SARS-CoV2. For example, our laboratory has reported fully human monoclonal antibodies m336, m337 and m338 with super strong MERS-CoV surface glycoprotein binding activity. They have all been shown to have extremely high virus neutralizing activity, with a half-inhibitory concentration (IC50) of 0.05 to 0.017ug / ml for MERS-CoV pseudovirus (Current Opinion in Pharmacology, 2008.8(5): p.600-608.). Among them, the m336 antibody has the strongest neutralizing activity, with an inhibition rate of up to 90% (IC50) on Huh-7 cells infected with MERS pseudovirus at a concentration as low as 0.039ug / ml. 90). Similarly, m336 showed effective inhibition of CPE induced by MERS-CoV live virus infection in Vero E6 cells, with an IC 50 It is 0.07ug / ml.
[0005] Although monoclonal antibody drugs are effective in preventing and treating infectious diseases, the molecular weight of full-length monoclonal antibody IgG is too large (about 150 kDa), which leads to high production costs and high prices for monoclonal antibody drugs, hindering their large-scale clinical application in economically underdeveloped areas, especially malaria-endemic areas (such as Southeast Asia and Africa). For a long time, people have been exploring the use of "antibody fragments" with smaller molecular weights that can be soluble and expressed in prokaryotic cells to replace monoclonal antibodies in the form of IgG as a new generation of antibody drugs with low production costs and strong tissue penetration (Nat Biotechnol, 2005.23(9):p.1126-1136; Current Opinion in Pharmacology, 2008.8(5):p.600-608). In recent years, a class of antibodies containing only the variable region of the heavy chain has been discovered in alpaca serum. It is the smallest antibody fragment that exists in nature and has the ability to bind to antigens. It is called nanobody (VHH) or single domain antibody (sdAb) (Protein Engineering, 1994.7(9):p.
[0006] 1129-1135.). These nanobodies have high antigen affinity and specificity, similar to full-length IgG monoclonal antibodies. More importantly, these antibodies are easier to modify and can be expressed in prokaryotic systems, so the preparation cost is very low (Front Immunol, 2017.8: p.1802.). However, these small molecule antibodies are currently mainly derived from camels or sharks, and are prone to produce immune responses in the human body, thus limiting their clinical application. Although animal-derived nanobodies can be humanized through genetic engineering technology, the antibodies are prone to lose thermal stability and it is difficult to maintain antibody affinity during this process. Recently, it has been discovered that a certain heavy chain variable region subfamily of humans also has excellent stability, solubility, low aggregation, excellent expression and purification yield, and characteristics suitable for phage display systems (J Mol Biol, 2008.382(3): p.779-789.). Based on these findings, we used this heavy chain variable region subfamily as a framework, introduced the heavy chain CDR regions (CDR1, CDR2, CDR3) of all antibody subfamilies from healthy adults and newborns, and constructed a fully human nanobody phage display library. This antibody library can be used to screen for specific fully human nanobodies targeting targets related to cancer (Front Oncol, 2018.8: p.539.), viruses (J Virol, 2017.91(20): p.e00937-17.) and immune cells (Sci Rep, 2017.7(1): p.9130.).
[0007] Therefore, we screened for fully human single-domain antibodies with high affinity, high specificity, and high neutralizing activity against the surface receptor glycoprotein of Henipavirus, hoping that they would serve as a specific drug to provide important guarantees for the clinical treatment of epidemics caused by Henipavirus infection and the prevention and control of the spread of the epidemic, and also provide new ideas for the development of vaccines. Summary of the invention
[0008] In order to solve the above technical problems, the present invention uses phage display technology to obtain a fully human single-domain antibody that specifically binds to the Hendra virus surface receptor glycoprotein G, cross-reactive with two common viruses of Nipah virus in the Henipavirus genus, and neutralizing activity with the corresponding pseudovirus of the Henipavirus genus. The present invention provides fully human single-domain antibodies that bind to the Henipavirus G protein, including Nb25 and Nb25.1. The present invention also relates to the use of antigen-binding fragments, bispecific antibodies, immunoconjugates and fusion proteins of these single-domain antibodies. The single-domain antibodies involved in the present invention can be developed as diagnostic products or candidate therapeutic drugs for Henipavirus infection.
[0009] The present invention provides an antibody molecule binding to Henipavirus, characterized in that it comprises at least one immunoglobulin single variable domain, and the immunoglobulin single variable domain is the sequence shown in SEQ ID NO:1 or SEQ ID NO:2.
[0010] Preferably, the immunoglobulin single variable domain comprises an amino acid sequence that is at least 90%, more preferably at least 95%, and even more preferably at least 99% identical to any one of the amino acid sequences in SEQ ID NO: 1 or SEQ ID NO: 2.
[0011] Preferably, the immunoglobulin single variable domain is a heavy chain variable region (VH).
[0012] Preferably, the heavy chain variable region (VH) is fully human.
[0013] Preferably, the K of the antibody molecule binding to the Henipavirus and the surface receptor glycoprotein of the Henipavirus genus is D Value less than 1×10 -8 M.
[0014] The present invention provides a bispecific antibody, characterized in that it contains any one of the above-mentioned antibody molecules.
[0015] Preferably, the bispecific antibody can specifically bind to Henipavirus, or to Kp1 binding to Henipavirus surface receptor glycoprotein. D Value less than 1×10 -7 M or neutralize Henipavirus.
[0016] The present invention provides a fusion protein, characterized in that it comprises any one of the above-mentioned antibody molecules, or any one of the above-mentioned bispecific antibodies, fused with a heterologous protein.
[0017] Preferably, the heterologous protein is human immunoglobulin Fc, more preferably human IgG1 Fc.
[0018] Preferably, any of the fusion proteins can specifically bind to the bispecific antibody that can specifically bind to the henipavirus, or to the K binding site of the henipavirus surface receptor glycoprotein. D Value less than 1×10 -8 M or neutralize Henipavirus.
[0019] The present invention provides a conjugate, characterized in that the conjugate comprises any one of the above-mentioned antibody molecules, or any one of the above-mentioned bispecific antibodies, or any one of the above-mentioned fusion proteins, coupled with an effector molecule.
[0020] Preferably, the effector molecule is a detectable label.
[0021] Preferably, the detectable label is a fluorescent label, a radioactive label, avidin, biotin, or an enzyme.
[0022] Preferably, any of the conjugates can specifically bind to the bispecific antibody that can specifically bind to the henipavirus, or to the K binding site of the henipavirus surface receptor glycoprotein. D Value less than 1×10 -8 M or neutralize Henipavirus.
[0023] The present invention provides a nucleic acid encoding any of the antibodies described above. The present invention provides a plasmid comprising the nucleic acid, optionally operably linked to a regulatory sequence. The present invention provides a host cell comprising the vector, and a method for producing and optionally recovering the single domain antibody or antigen binding fragment. The host cell of the present invention can be any prokaryotic cell or eukaryotic cell, including but not limited to bacterial cells (e.g., Escherichia coli), insect cells (e.g., using a baculovirus expression system), yeast or mammalian cells (e.g., CHO or BHK cell lines). Other suitable host cells are known to those skilled in the art. Preferably, the host cell is an Escherichia coli cell, which has a short culture cycle and low production cost.
[0024] The antibody or bispecific antibody provided by the present invention can specifically bind to the corresponding antigen, and the antigen refers to all substances that can induce an immune response in the body. The antigen includes but is not limited to small molecule compounds. The antigen includes but is not limited to the following proteins, subunits, domains, motifs and epitopes belonging to the following proteins: CD2, CD3, CD3E, CD4, CD11, CD11a, CD14, CD16, CD18, CD19, CD20, CD22, CD23, CD25, CD28, CD29, CD30, CD32, CD33 (p67 protein), CD38, CD40, CD40L, CD52, CD54, CD56, CD80, CD147, GD3, IL-1, IL-1R, IL-2, IL-2R, IL-4 , IL-5, IL-6, IL-6R, IL-8, IL-12, IL-15, IL-18, IL-23, interferon-α, interferon-β, interferon-γ; TNF-α, TNFβ2, TNFc, TNFαβ, TNF-RI, TNF-RII, FasL, CD27L, CD30L, 4-1BBL, TRAIL, RANKL, TWEAK, APRIL, BAFF, LIGHT, VEGI, OX40L, TRAIL receptor-1, A1 adenosine receptor, lymphotoxin beta receptor, TACI, BAFF-R, EPO;LFA-3, ICAM-1, ICAM-3, EpCAM, β1-integrin, β2-integrin, α4 / β7-integrin, α2-integrin, α3-integrin, α4-integrin, α5-integrin, α6-integrin, αv-integrin, αVβ3-integrin, FGFR-3, keratinocyte growth factor, VLA-1, VLA-4, L-selectin, anti-idiotypic antibody (anti-id), E-selectin, HLA, HLA-DR, CTLA-4, T cell receptor, B7-1, B7-2, VNRintegrin, TGF-β1, TGF-β2, Eotaxin 1, BLyS (B-lymphocyte stimulator), complement C5, IgE, factor VII, CD64, CBL, NCA90, EGFR (ErbB-1), Her2 / neu (ErbB-2), Her3 (ErbB-3), Her4 (ErbB-4), tissue factor, VEGF, VEGFR, endothelin receptor, VLA-4, hapten NP-capped or NIP-capped protein, T cell receptor α / β, E-selectin, digoxin, placental alkaline phosphatase (PLAP) and testicular PLAP-like alkaline phosphatase, transferrin receptor, carcinoembryonic antigen (CEA), CEACAM5, HMFG PEM, mucin MUC1, MUC18, heparanase I, human cardiac myosin, tumor-associated glycoprotein-72 (TAG-72), tumor-associated antigen CA125, prostate-specific membrane antigen (PSMA), high molecular weight melanoma-associated antigen (HMW-MAA), cancer-associated antigen, Gcoprotein IIb / IIIa (GPIIb / IIIa), tumor-associated antigen expressing Lewis Y-related carbohydrate, human cytomegalovirus (HCMV) gH envelope glycoprotein, HIV gp120, HIV gp140, HCMV, respiratory syncytial virus RSVF, RSVF Fgp, VNR integrin, IL-8, cytokeratin tumor-associated antigen, Hep B gp120, CMV, gpIIbIIIa, HIVIIIB gp120V3 loop, respiratory syncytial virus (RSV) Fgp, herpes simplex virus (HSV) gD glycoprotein, HSV gB glycoprotein, HCMV gB envelope glycoprotein and Clostridium perfrmgens toxin, programmed death-1 (PD-1). ;
[0025] Those skilled in the art will understand that the targets listed above refer not only to specific proteins and biomolecules, but also to biochemical pathways or various pathways containing them. For example, when CTLA-4 is mentioned as a target antigen, it means that the ligand and receptor constitute the T cell co-stimulatory pathway, including CTLA-4, B7-1, B7-2, CD28, and any other undiscovered ligand or receptor is also a target object. Therefore, the target used in this article refers not only to a specific biomolecule, but also to a group of proteins that interact with the target and the members of the biochemical pathway to which the target belongs. Those skilled in the art will further understand that any of the above-mentioned target antigens, the ligands or receptors connected to them, or other members of their corresponding biochemical pathways can be operably connected to the single domain antibody or antigen binding fragment of the present invention to produce a fusion. Thus, in fact any polypeptide, whether a ligand, a receptor or some other protein or protein domain, including but not limited to the above-mentioned targets and the proteins that constitute their corresponding biochemical pathways, can be operably connected to the single domain antibody or antigen binding fragment of the present invention to form a fusion.
[0026] More preferably, the sources of the antigens include, but are not limited to, cancer, infectious diseases (such as viral, bacterial, fungal, parasitic infections, etc.), autoimmune diseases, and inflammatory disorders.
[0027] The antigen may be from a virus. The virus described in the present invention is, for example, a virus from one of the following families: Retroviridae (e.g., human immunodeficiency virus (HIV), human T-cell leukemia virus (HTLV)); Picornaviridae (e.g., poliovirus, hepatitis A virus, hepatitis C virus, enterovirus, human coxsackievirus, rhinovirus, echovirus, foot-and-mouth disease virus); Cadmyxoviridae (e.g., strains causing gastroenteritis); Togaviridae (e.g., equine encephalitis virus, rubella virus); Flaviviridae (e.g., , dengue virus, yellow fever virus, West Nile virus, St. Louis encephalitis virus, Japanese encephalitis virus, and other encephalitis viruses); Coronaviridae (e.g., coronavirus, severe acute respiratory syndrome (SARS) virus); Rhabdoviridae (e.g., vesicular stomatitis virus, rabies virus); Paramyxoviridae (e.g., parainfluenza virus, mumps virus, measles virus, respiratory syncytial virus (RSV)); Orthomyxoviridae (e.g., influenza virus); Bunyaviridae (e.g., Hantavirus, Sin Nombre virus, Rift Valley fever virus, bunya virus, phleboviruses, and Nairo virus); Arenaviridae (e.g., hemorrhagic fever virus, Machupo virus, Junin virus); Reoviridae (e.g., reovirus, orbiviurse, and rotavirus); Binaviridae; Hepadnaviridae (e.g., hepatitis B virus); Parvoviridae (e.g., parvovirus); Papovaviridae (e.g., papillomavirus, polyomavirus, BK virus); Adenoviridae (e.g., most adenoviruses, such as adeno-associated virus); Herpesviridae (e.g., , herpes simplex virus (HSV-1 and HSV-2), cytomegalovirus (CMV), Epstein-Barr virus (EBV), varicella zoster virus (VZV), and other herpes viruses, including HSV-6); Poxviridae (e.g., smallpox virus, vaccinia virus, poxvirus); and Iridoviridae (e.g., African swine fever virus); Viridae (e.g., Ebola virus, Marburg virus); Caliciviridae (e.g., Norwalk virus), and unclassified viruses (e.g., the causative agent of spongiform encephalopathies, the causative agent of hepatitis delta (thought to be a defective satellite of hepatitis B virus), and astroviruses).
[0028] The antigen may be derived from bacteria. The bacteria of the present invention include Helicobacter pylori, Borelia burgdorferi, Legionella pneumophila, Mycobacterium (such as M. tuberculosis, M. avium, M. intracellulare, M. kansaii, M. gordonae), Staphylococcus aureus, Neisseria gonorrhoeae, Neisseria meningitidis, Listeria monocytogenes, Streptococcus pyogenes (Group A Streptococcus), Streptococcus agalactiae (Group B Streptococcus), and Streptococcus pyogenes (Group B Streptococcus). bacteria), Streptococcus (green fly group), Streptococcus faecalis, Streptococcus bovis, Streptococcus (anaerobic), Streptococcus pneumoniae, pathogenic Campylobacter, Enterococcus, Haemophilus influenzae, Bacillus anthracis, Corynebacterium diphtheriae, Corynebacterium, swine fever virus, Clostridium perfringens, Clostridium tetani, Enterobacter aerogenes, Klebsiella pneumoniae, Pasteurella multocida, Bacteroides, Clostridium, Streptomyces maltophilus, Treponema pallidum, Treponema, Leptospira or Actinomyces israelli.
[0029] The antigen may be derived from a fungus, such as Cryptococcus neoformans, Histoplasma capsulatum, Coccidioides immitis, Blastomyces dermatitidis, Chlamydia trachomatis or Candida albicans.
[0030] The antigen may be derived from a parasite, such as Plasmodium falciparum or Toxoplasma gondii.
[0031] The antigen may be a cancer antigen, such as a solid tumor or a blood-borne cancer antigen. The solid tumor of the present invention is a sarcoma or carcinoma, such as a fibrosarcoma, a myxosarcoma, a liposarcoma, a chondrosarcoma, an osteogenic sarcoma, or another sarcoma, a synovioma, a mesothelioma, an Ewing's tumor, a leiomyosarcoma, a rhabdomyosarcoma, a colon cancer, a lymphoid malignancy, a pancreatic cancer, a breast cancer, a lung cancer, an ovarian cancer, a prostate cancer, a hepatocellular carcinoma, a squamous cell carcinoma, a basal cell carcinoma, adenocarcinoma, a sweat gland carcinoma, a sebaceous gland carcinoma, a papillary carcinoma, a papillary adenocarcinoma, a medullary carcinoma, a bronchogenic carcinoma, a renal cell carcinoma, a hepatocellular carcinoma, a bile duct carcinoma, a choriocarcinoma, a Wilms' tumor, a cervical cancer, a testicular tumor, a bladder cancer, or a central nervous system tumor (such as a glioma, an astrocytoma, a medulloblastoma, a craniopharyngioma, an ependymoma, a pineal gland, a hemangioblastoma, an acoustic neuroma, an oligodendroglioma, a hemangioma, a melanoma, a neuroblastoma, or a retinoblastoma). The blood-borne cancer described in the present invention is a leukemia, such as acute leukemia (such as acute lymphocytic leukemia, acute myeloid leukemia, acute myeloid leukemia and myeloblastic, promyelocytic, myelomonocytic, monocytic and erythroleukemia); chronic leukemia (such as chronic myeloid (granulocytic) leukemia, chronic myeloid leukemia and chronic lymphocytic leukemia), polycythemia vera, lymphoma, Hodgkin's disease, non-Hodgkin's lymphoma (indolent and advanced forms), multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, myelodysplastic syndrome, hairy cell leukemia or myelodysplasia. Tumor antigens are well known in the art, including, for example, carcinoembryonic antigen (CEA), β-human chorionic gonadotropin (β-HCG), alpha-fetoprotein (AFP), lectin-reactive AFP, (AFP-L3), thyroglobulin, RAGE-1, MN-CAIX, human telomerase reverse transcriptase (hTERT), RU1, RU2 (AS), intestinal carboxylesterase, muthsp70-2, M-CSF, prostaglandinase, prostate-specific antigen (PSA), PAP, NY-ESO-1, LAGE-1a, p53, prostein, PSMA, Her2 / neu, survival protein and telomerase, prostate cancer tumor antigen-1 (PCTA-1), melanoma-associated antigen (MAGE), ELF2M, neutrophil elastase, ephrinB2 and CD22. It can also be any cancer-related protein, such as IGF-I, IGF-II, IGR-IR or mesothelin.
[0032] The present invention provides a pharmaceutical composition, which is prepared by mixing an effective preventive or therapeutic dose of the antibody or antigen-binding fragment, bispecific antibody, fusion protein, conjugate, nucleic acid molecule of the antibody or antigen-binding fragment, plasmid and a physiologically or pharmaceutically acceptable carrier, excipient or stabilizer of the present invention, and the composition includes but is not limited to a lyophilized dosage form, an aqueous solution dosage form, a liposome or a capsule dosage form, etc. The concentration of the antibody or antigen-binding fragment, bispecific antibody, fusion protein, conjugate, nucleic acid molecule of the antibody or antigen-binding fragment, plasmid of the present invention can be varied from about 0.1% to 100% (by weight). BRIEF DESCRIPTION OF THE DRAWINGS
[0033] Figure 1 : ELISA was used to detect the binding of single domain antibodies to Hendra virus surface glycoprotein G.
[0034] Figure 2 : ELISA was used to detect the binding of single domain antibodies to surface glycoprotein G of different species of the Henipavirus family.
[0035] Figure 3 :Using ForteBio to detect the binding of Hendra virus HEVG and single domain antibody Nb25.
[0036] Figure 4 :Using ForteBio to detect the binding of Hendra virus HEVG to the single domain antibody Nb25.1.
[0037] Figure 5 :Using ForteBio to detect the binding of Nipah virus in Malaysia NiVMG and single domain antibody Nb25.
[0038] Figure 6 :Using ForteBio to detect the binding of Nipah virus in Malaysia NiVMG and single domain antibody Nb25.1.
[0039] Figure 7 :Using ForteBio to detect the binding of Nipah virus in Bangladesh strain NiVBG and single domain antibody Nb25.
[0040] Figure 8 :Using ForteBio to detect the binding of Nipah virus in Bangladesh strain NiVBG and single domain antibody Nb25.1.
[0041] Fig. 9 :Using ForteBio to detect the competitive binding between the single-domain antibody Nb25.1 and the receptor ephrin B2.
[0042] Fig.10 :Using ForteBio to detect the competitive binding between single domain antibody Nb25.1 and antibody m102.4.
[0043] Fig.11 :Using ForteBio to detect the competitive binding between the single-domain antibody Nb25.1 and the antibody HENV-26.
[0044] Fig.12 :Using ForteBio to detect the competitive binding between the single-domain antibody Nb25.1 and the antibody HENV-32.
[0045] Fig.13 : Using ForteBio to detect the competitive binding between the single-domain antibody Nb25.1 and the antibody nAH.1.3.
[0046] Fig.14 : Using ForteBio to detect the competitive binding between the single-domain antibody Nb25.1 and the antibody hAH.1.3.
[0047] Fig.15 : The neutralizing activity of Nb25.1 against Hendra virus was detected using a pseudovirus system.
[0048] Fig.16 : The neutralizing activity of Nb25.1 against the Malaysian strain of Nipah virus was detected using a pseudovirus system.
[0049] Fig.17 : The neutralizing activity of Nb25.1 against the Bangladeshi strain of Nipah virus was detected using the pseudovirus system.
[0050] Fig.18 : The neutralizing activity of Nb25.1 and m102.4 against the Malaysian strain of Nipah virus was detected using a pseudovirus system.
[0051] Fig.19 :The pseudovirus system was used to detect the infection inhibitory activity of Nb25.1 against the Malaysian strain of Nipah virus in vivo.
[0052] Fig. 20 : ELISA was used to detect the binding of Nb25.1-Fc to the surface glycoprotein G of different species of the Henipavirus family.
[0053] Fig.21 :Using ForteBio to detect the binding of Nb25.1-Fc to Hendra virus HEVG.
[0054] Fig. 22 :ForteBio was used to detect the binding of Nb25.1-Fc to Nipah virus in Malaysia NiVMG.
[0055] Fig.23 :ForteBio was used to detect the binding of Nb25.1-Fc to Nipah virus in Bangladesh NiVBG.
[0056] Fig.24 : The neutralizing activity of Nb25.1-Fc against Hendra virus was detected using a pseudovirus system.
[0057] Fig.25 : The neutralizing activity of Nb25.1-Fc against the Malaysian strain of Nipah virus was detected using a pseudovirus system.
[0058] Fig.26 : The neutralizing activity of Nb25.1-Fc against the Bangladeshi strain of Nipah virus was detected using the pseudovirus system.
[0059] Fig. 27 :The pseudovirus system was used to detect the infection inhibitory activity of Nb25.1-Fc against the Nipah virus Malaysian strain in vivo. DETAILED DESCRIPTION OF THE INVENTION
[0061] In order to more thoroughly understand the invention, some definitions are listed below. The above definitions are intended to include grammatical equivalents.
[0062] "Antibody molecule" herein means a protein consisting of one or more domains encoded by all or part of a generally recognized immunoglobulin gene. The recognized immunoglobulin genes, for example, in humans, include kappa (κ), lambda (λ) and heavy chain loci, which contain numerous variable region genes, and constant region genes mu (μ), delta (δ), gamma (γ), epsilon (ε), alpha (α) encoding IgM, IgD, IgG, IgE and IgA isotypes, respectively. Antibodies herein are meant to include full-length antibodies, individual chains thereof, and all parts, domains or fragments thereof, as well as natural antibodies from any organism, engineered antibodies, or antibodies recombinantly produced for experimental, therapeutic purposes or other purposes as further specified below. The term "antibody" includes antibody fragments, as known in the art, such as Fab, Fab', F(ab')2, Fv, scFv or the antigen binding domain of an antibody (e.g., VHH domain or VH / VL domain), or antibody fragments produced by modifying a whole antibody or those synthesized de novo using recombinant DNA technology. The term "antibody" includes monoclonal as well as polyclonal antibodies. Antibodies can be antagonists, agonists, neutralizing antibodies, or inhibitory antibodies, or stimulating antibodies. The antibodies of the present invention can be non-human antibodies, chimeric antibodies, humanized antibodies or fully human antibodies.
[0063] Specifically included within the definition of "antibody" are non-glycosylated antibodies. Preferably, as used herein, "non-glycosylated antibody" means an antibody lacking a carbohydrate attached at position 297 of the Fc region, wherein numbering is according to the EU system of Kabat. The non-glycosylated antibody may be a deglycosylated antibody, which is an antibody from which the Fc carbohydrate has been removed, for example chemically or enzymatically. Alternatively, the non-glycosylated antibody may be a non-glycosylated or unglycosylated antibody, which is an antibody expressed without the Fc carbohydrate, for example by mutating one or more residues encoding a glycosylation pattern or by expressing in an organism such as bacteria that does not attach carbohydrates to proteins.
[0064] As used herein, "IgG" means a polypeptide belonging to the class of antibodies, which is substantially encoded by the recognized immunoglobulin gamma gene. In humans, this class includes IgG1, IgG2, IgG3 and IgG4. In mice, this class includes IgG1, IgG2a, IgG2b, IgG3. Herein, "immunoglobulin (Ig)" means a protein consisting of one or more polypeptides substantially encoded by immunoglobulin genes. Immunoglobulins include, but are not limited to, antibodies. Immunoglobulins can have many structural types, including, but not limited to, full-length antibodies, antibody fragments, and single immunoglobulin domains. The known Ig domains VH, Cγi, Cγ2, Cγ3, VL, and CL in the antibody IgG class.
[0065] As used herein, "antigen" means a compound, composition or substance that can stimulate antibody production or T cell response in an animal, including compositions injected or absorbed into an animal, which may be proteins, carbohydrates, lipids or other pathogens.
[0066] As used herein, "immunoglobulin single variable domain" means an immunoglobulin variable domain that is capable of specifically binding to an antigenic epitope without pairing with other immunoglobulin variable domains. An example of an immunoglobulin single variable domain within the meaning of the present invention is a "domain antibody", such as a VH domain antibody herein.
[0067] As used herein, "heavy chain variable region (VH)" refers to the region of the immunoglobulin heavy chain near the N-terminal amino acid sequence with large changes, which is the heavy chain variable region domain in conventional 4-chain antibodies. It is particularly used to distinguish VHH antibodies of the Camelidae family.
[0068] As used herein, "identity" refers to the similarity between nucleotide or amino acid sequences, alternatively referred to as sequence identity. Sequence identity is typically measured in terms of percentage identity (or similarity or homology); the higher the percentage, the more similar the two sequences are. Homologues or variants will have a relatively high degree of sequence identity when aligned using standard methods. Sequence alignment methods for comparison are well known in the art. Various programs and alignment algorithms are described in: Smith and Waterman, Adv Appl. Math., 2:482, 1981; Needlema and Wunsch, J. Mol. Biol. 48:443, 1970; Pearson and Lipman, Proc. Natl. Acad. Sci. USA 85:2444, 1988; Higgins and Sharp, Gene 73:237-244, 1988; Higgins and Sharp, CABIOS 5:151-153, 1989; Corpet et al., Nucleic Acids Research 16:10881-10890, 1988; and Altschul et al., Nature Genet., 1994, 6:119-129.
[0069] The NCBI Basic Local Alignment Search Tool (BLAST™) (Altschul et al., J. Mol. Biol., 215:403-410, 1990) is available from several sources, including the National Center for Biotechnology Information (NCBI, Bethesda, Md.) and on the Internet for the programs blastp, blastn, blastx, tblastn and tblastx for sequence analysis.
[0070] As used herein, "bispecific antibody" refers to an artificial antibody that contains two specific antigen-binding sites.
[0071] As used herein, "fully human" means that the antibodies are entirely encoded by human antibody genes.
[0072] As used herein, "fusion protein" refers to the expression product of fusion genes, or two or more proteins fused by biological or chemical methods.
[0073] As used herein, "conjugate" means an antibody or protein molecule linked to another small molecule or macromolecule by biological or chemical methods.
[0074] As used herein, "amino acid" means one of the 20 naturally occurring amino acids or any non-natural analogs, which may be located at a specifically defined position. As used herein, "protein" means at least two covalently linked amino acids, which include proteins, polypeptides, oligopeptides and peptides. Proteins may be composed of naturally occurring amino acids and peptide bonds, or of synthetic peptide mimetic structures, which peptide mimics are "analogs". Therefore, as used herein, "amino acid" or "peptide residue" means naturally occurring and synthetic amino acids. For example, for the purposes of the present invention, homophenylalanine, citrulline and norleucine are considered amino acids for the purposes of the present invention. "Amino acid" also includes imino acid residues such as proline and hydroxyproline. The side chain may be in the (R) or (S) configuration. In a preferred embodiment, the amino acid is present in the (S) or L-configuration. If non-naturally occurring side chains are used, non-amino acid substitutions may be used, for example to prevent or delay degradation in vivo.
[0075] As used herein, "polypeptide" means a polymer in which the monomers are amino acid residues linked together by amide bonds. When the amino acids are α-amino acids, either the L-optical isomer or the D-optical isomer can be used. The terms "polypeptide" or "protein" as used herein are intended to encompass any amino acid sequence and include modified sequences, such as glycoproteins. The term "polypeptide" is particularly intended to encompass naturally occurring proteins, as well as recombinant or synthetically produced proteins.
[0076] " Nucleic acid " used herein means the polymer consisting of nucleotide units (ribonucleotides, deoxyribonucleotides, related naturally occurring structural variants and their synthesized non-naturally occurring analogs) by phosphodiester bonds. Therefore, the term includes nucleotide polymers, wherein nucleotides and the bonds therebetween include non-naturally occurring synthetic analogs, such as but not limited to thiophosphates, phosphoramidates, methyl phosphonates, chiral methyl phosphonates, 2'-O-methyl ribonucleotides, peptide nucleic acids (PNA) etc. For example, these polynucleotides can be synthesized using an automatic DNA synthesizer. The term " oligonucleotide " generally refers to short polynucleotides, generally not more than about 50 nucleotides. It should be understood that when the nucleotide sequence is represented by a DNA sequence (i.e. A, T, G, C), this also includes RNA sequences (i.e. A, U, G, C) in which "U" replaces "T".
[0077] Conventional notation is used herein to describe nucleotide sequences: the left-hand end of a single-stranded nucleotide sequence is the 5' end; the left-hand direction of a double-stranded nucleotide sequence is the 5' direction. The direction in which 5' to 3' nucleotides are added to the nascent RNA transcript is called the transcription direction. The DNA strand with the same sequence as the mRNA is called the coding strand.
[0078] As used herein, "plasmid" means a plasmid artificially constructed on the basis of a natural plasmid to adapt to laboratory operations. A nucleic acid molecule can be introduced into a host cell to produce a transformed host cell. A vector may include a nucleic acid sequence that allows it to replicate in a host cell, such as an origin of replication, and may also include one or more selectable marker genes and other genetic elements known in the art.
[0079] The "host cell" used herein is also called a recipient cell, and refers to a host cell that receives foreign genes during transformation and transduction (infection).
[0080] As used herein, "pharmaceutically acceptable carrier" means a conventional pharmaceutically acceptable carrier. Remington's Pharmaceutical Sciences, EW Martin, Mack Publishing Co., Easton, Pa., 15th edition (1975), describes compositions and formulations suitable for drug delivery of one or more therapeutic compounds or molecules (e.g., one or more antibodies), as well as additional agents.
[0081] "Effective preventive or therapeutic dose" herein means a certain amount of a specific agent sufficient to achieve the desired effect in a subject treated with the agent. The exact dose will depend on the purpose of the treatment and can be determined by those skilled in the art using known techniques. The dosage range may be 0.01-100 mg / kg body weight or greater, such as 0.1, 1, 10 or 50 mg / kg body weight, preferably 1-10 mg / kg. As is known in the art, adjustments may be necessary for antibody or Fc fusion degradation, systemic or local drug delivery and new protease synthesis rates, as well as age, weight, general health, sex, diet, administration time, drug interactions and severity of the disease, and can be determined by those skilled in the art by conventional experimental methods. Ideally, a therapeutically effective amount of an antibody is an amount sufficient to prevent, treat or improve an infection or disease. The therapeutically effective amount of an agent used to prevent, improve and / or treat a subject will depend on the subject being treated, the type and severity of the pain, and the mode of administration of the therapeutic composition.
[0082] As used herein, "coding" means the inherent properties of a specific nucleotide sequence in a polynucleotide, such as a gene, cDNA or mRNA, used as a template for synthesizing other polymers and macromolecules in a biological process with a determined nucleotide sequence, or a determined amino acid sequence and the resulting biological properties. Therefore, if the transcription and translation of the mRNA produced by the gene produces protein in a cell or other biological system, the gene encodes a protein. The coding strand (its nucleotide sequence is identical to the mRNA sequence and is generally provided in a sequence table) and the non-coding strand (used as a transcription template, gene or cDNA) can be referred to as a coded protein. Or other products of the gene or cDNA. Unless otherwise indicated, "nucleotide sequences encoding amino acid sequences" include all nucleotide sequences that are degenerate forms of each other and encode the same amino acid sequence. The nucleotide sequences encoding proteins and RNA may include introns.
[0083] Unless otherwise stated, all technical and scientific terms used herein have the same meaning as those generally understood by those of ordinary skill in the art to which the present disclosure belongs. Unless the context clearly indicates otherwise, the singular terms "a", "an" and "the" include plural indicators. It should also be understood that all base sizes or amino acid sizes given for nucleic acids or polypeptides, and all molecular weights or molecular weight values are approximate and are provided for description. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, suitable methods and materials are described below. The term "comprising" means "including". All publications, patent applications, patents and other references mentioned herein are incorporated by reference in their entirety. In the event of a conflict, this specification (including term explanations) shall prevail. In addition, materials, methods and embodiments are illustrative only and not restrictive. DETAILED DESCRIPTION
[0084] The standard recombinant DNA technology and molecular cloning techniques used in the examples are well known in the art (Ausubel, FM et al., Current Protocols in Molecular Biology, published by Greene Publishing Assoc. and Wiley-Interscience), and the materials and methods suitable for microbial growth are well known in the art. The main chemical and biological reagents were purchased from KAPABiosystems, New England Biolabs, TransGenBiotech, Thermo Fisher Scientific, OMEGAbio-tek, etc.
[0085] The present invention is described in detail below with reference to specific embodiments.
[0086] Example 1 Screening of high-affinity single domain antibodies against Hendra virus surface receptor glycoprotein G
[0087] Using CDR transplantation technology, the heavy chain variable regions including CDR1, CDR2 and CDR3 in the existing phage antibody library in the laboratory (Cell Host Microbe. 2017.22 (4): 471-483.e5.; Emerg Microbes Infect. 2017.6 (10): e89.) were cloned into the human IGHV germline family 1-66*01 backbone, and finally the nucleic acid fragment encoding the full-length heavy chain variable region was amplified by nested PCR. The nucleic acid fragment of the heavy chain single domain antibody was then cloned into the phage display vector pComb3x (Addgene, product number: 63891), and the ligation product was electrotransformed into the Escherichia coli electrotransformation competent TG1 to construct a heavy chain single domain antibody phage display library with a library capacity of more than 100 billion. Then the antibodies were screened against the biotin-labeled Hendra virus G protein (purchased from Sino Biological, product number: 40335-V02H). The specific steps are as follows: fix the biotin-labeled Hendra virus G protein on streptavidin-coated magnetic beads, 12 The phages displaying antibodies were incubated with 5, 4, 2, and 1 μg of antigen at room temperature for two hours in rounds 1, 2, 3, and 4, respectively. 10 phages were used in each round of screening. 12 The phages obtained in the third and fourth rounds of screening were selected to infect TG1 cells and clones were randomly selected for monoclonal phage ELISA, and further sequencing was performed to identify single domain antibodies that bind to the G protein of Hendra virus.
[0088] Example 2 Preparation, expression and purification of antibodies
[0089] Four clones were selected based on the sequencing results, and their soluble expression products were prepared basically according to the literature (Cell Host Microbe. 2017. 22 (4): 471-483.e5.). Specifically, the plasmids of the four clones were transferred into HB2151 competent cells, and a single colony was picked from an overnight ampicillin plate, inoculated with SB bacterial culture medium, and expressed for 12-14 hours under IPTG induction conditions at 30 degrees. The bacteria were harvested and the single domain antibody was purified from them using Ni-TNA.
[0090] Example 3 Detection of the binding ability of single domain antibodies to Hendra virus G protein
[0091] 200 ng of Hendra virus G protein was coated on an ELISA plate overnight at 4°C, and single-domain antibodies with gradient dilutions were added for incubation. Anti-FLAG-HRP antibody (purchased from SIGMA) was used to detect the binding ability of single-domain antibodies to Hendra virus G protein. The results showed that single-domain antibodies have a strong ability to bind to Hendra virus G protein ( Figure 1 ), among which Nb25 had the strongest binding ability, with an EC50 of 12.32 nM.
[0092] Example 4 Binding kinetics of single domain antibodies to Hendra virus G protein
[0093] The binding activity of the single-domain antibody Nb25 to the G protein of Hendra virus was determined using BLI technology (Emerg Microbes Infect. 2017.6(10):e89.). The G protein of Hendra virus was fixed to an amino-coupled sensor (AR2Gbiosensor) (Pall Fortebio), and the antibody solution with gradient dilution was used as the analysis sample. The steps are as follows: The G protein of Hendra virus was diluted to 10 μg / ml with sodium acetate solution (pH 5.0), then immobilized on the AR2Gbiosensor, and combined with a 3-fold gradient dilution of the antibody solution (concentration range of 1000-12.4 nM) in running buffer (PBST), where no antibody was added to the blank control well. The program settings were: Association, 300 s; Dissociation, 300 s, and the temperature was set to 37 °C. ForteBio Data analysis 10.1 software was used to analyze the data. The corresponding blank control wells were used as controls to subtract the background, and the curves of each concentration were fitted according to the Mass Transport binding mode to obtain the kinetic analysis results. The report shows the equilibrium constant (K D )value( Figure 2 ).
[0094] Example 5 Affinity maturation of single domain antibodies
[0095] Primers were designed based on the antibody sequence to perform random scanning and random mutation on the CDR region of the single-domain antibody, and then transformed into Rosetta competence. Then, clones were randomly selected for monoclonal phage ELISA, and further sequencing was performed to identify the single-domain antibody that binds to the G protein of Hendra virus.
[0096] Example 6 Production of Henipavirus Surface Receptor Glycoprotein G Protein.
[0097] The gene encoding amino acids 1-602 (604) of Henipavirus surface receptor glycoprotein G (Gene ID: 1446471, Gene ID: 920955, GenBank: JN808864.1, Gene ID: 20964376, Gene ID: 20964673, Gene ID: 20712670) was synthesized by BGI on the pcDNA3.1 vector, and amino acids 167-602 (604) were constructed into a pSecTag2B expression vector (Thermo Fisher, product number: V90020) with an IgG1 Fc tag and an Avi-tag (GLNDIFEAQKIEWHE) at its C-terminus. The PsecTag-Fc recombinant plasmid was transfected into Expi293 cells (ThermoFisher, product number: A14635) for transient expression and purified using Protein G (GE Healthcare, product number: 17061805).
[0098] Example 7 Binding kinetics of single domain antibody Nb25.1 to Hendra virus G protein
[0099] The binding activity of the single-domain antibody Nb25.1 to the surface receptor glycoprotein G protein of different henipaviruses was determined by BLI technology (Emerg Microbes Infect. 2017.6(10):e89.). The steps are as follows: The G protein of Hendra virus was fixed to an amino-coupled sensor (AR2G biosensor) (Pall Fortebio), and the antibody solution with gradient dilution was used as the analysis sample. The steps are as follows: The G protein of Hendra virus was diluted to 10μg / ml with sodium acetate solution (pH 5.0), then immobilized on the AR2G biosensor, and combined with a 3-fold gradient dilution of the antibody solution (concentration range of 100-1.2nM) in running buffer (PBST), in which no antibody was added to the blank control well. The program settings were: Association, 600s; Dissociation, 600s, and the temperature was set to 37°C. The data were analyzed using ForteBio Data analysis10.1 software. The corresponding blank control wells were used as controls to subtract the background, and the curves of each concentration were fitted according to the Mass Transport binding mode to obtain the kinetic analysis results. The report shows the equilibrium constant (K D )value( Figure 3 ).
[0100] Example 8 Detection of cross-binding activity of single domain antibody Nb25.1
[0101] The G proteins of different henipavirus genera were coated on ELISA plates at a concentration of 200 ng overnight at 4 degrees, and single-domain antibodies with gradient dilutions were added for incubation. The binding ability of single-domain antibodies to G proteins of different henipavirus genera was detected with anti-FLAG-HRP antibody (purchased from SIGMA). The results showed that the single-domain antibody Nb25.1 had a strong ability to bind to G proteins of different henipavirus genera ( Figure 4 ), among which Nb25.1 had the strongest binding ability to the G protein of Hendra virus, with an EC50 of 1.716nM.
[0102] Example 9 Binding kinetics of single domain antibody Nb25.1 to different henipavirus G proteins
[0103] The binding activity of the single-domain antibody Nb25.1 to the surface receptor glycoprotein G protein of different henipaviruses was determined by BLI technology (Emerg Microbes Infect. 2017.6(10):e89.). The steps are as follows: The G protein of Hendra virus was fixed to an amino-coupled sensor (AR2G biosensor) (Pall Fortebio), and the antibody solution with gradient dilution was used as the analysis sample. The steps are as follows: The G protein of Hendra virus was diluted to 10μg / ml with sodium acetate solution (pH 5.0), then immobilized on the AR2G biosensor, and combined with a 3-fold gradient dilution of the antibody solution (concentration range of 1000-12.4nM) in running buffer (PBST), in which no antibody was added to the blank control well. The program settings were: Association, 600s; Dissociation, 600s, and the temperature was set to 37°C. ForteBio Data analysis10.1 software was used to analyze the data. The corresponding blank control wells were used as controls to subtract the background, and the curves of each concentration were fitted according to the Mass Transport binding mode to obtain the kinetic analysis results. The report shows the equilibrium constant (K D )value( Figure 5-Figure 10 ).
[0104] Example 10: Competition assay of single domain antibody Nb25.1 for binding to ephrin B2
[0105] The single-domain antibody Nb25.1 was used to compete with the G protein of Hendra virus, using the receptor protein ephrin B2 as the competitor. The steps are as follows: The G protein of Hendra virus was fixed to an amino-coupled sensor (AR2G biosensor) (Pall Fortebio), reacted with a 15μg / ml first antibody solution (Nb25.1) for 300s, and then reacted with a mixed solution containing 15μg / ml of the receptor protein ephrin B2 and 15μg / ml of the first antibody, and a kinetic curve was drawn. The results showed that the single-domain antibody Nb25.1 did not have a competitive epitope with the receptor protein ephrin B2 ( Fig.11 ).
[0106] Example 11 Binding competition assay of single domain antibody Nb25.1 against m102.4, HENV-26, HENV-32, nAH1.3 and hAH1.3
[0107] Using different antibodies as competitors, the single-domain antibody Nb25.1 was subjected to competitive binding with the G protein of Hendra virus. The steps are as follows: The G protein of Hendra virus was fixed to an amino-coupled sensor (AR2Gbiosensor) (PallFortebio), reacted with a 15μg / ml first antibody solution (Nb25.1) for 300s, and then reacted with a mixed solution containing 15μg / ml of different antibodies and 15μg / ml of the first antibody, and a kinetic curve was drawn. The results showed that the single-domain antibody Nb25.1 did not have a competitive epitope with the receptor protein ephrinB2 ( Figure 12-16 ).
[0108] Example 12 Pseudovirus system to detect the neutralizing activity of Nb25.1 and antibody combination
[0109] The G protein-deficient VSV pseudovirus particles carrying the R-luciferase reporter gene were transfected with a plasmid (pMD2.G) containing VSV-G protein, and the supernatant was harvested 72 hours later. The two recombinant plasmids containing the receptor glycoprotein G and fusion protein F on the surface of the henipa virus were co-transfected into 293T cells. After 6 hours, the supernatant infected with VSV-G was added, and then the supernatant was harvested after continuing to culture for 72 hours. The supernatant at this time was the packaged pseudovirus particles of the henipa virus. The antibody was diluted with a cell culture medium containing 10% serum to a final concentration of 200-6.3μg / ml, and then 50μl of the diluted antibody was mixed with 50μl of the virus and added to Huh-7 cells. After culturing at 37℃ for 12 hours, fresh culture medium was replaced and cultured for another 48 hours. The relative fluorescence value in the cell lysate was detected using Promega's LuciferaseAssay Kit. The results showed that the single-domain antibody Nb25.1 had a neutralizing effect on the three major prevalent henipa viruses. The neutralization activity against Nipah virus is stronger than that against Hendra virus, and 10 μg / ml still has 90% neutralization ( Fig.17 The combination of single-domain antibody Nb25.1 and monoclonal antibody m102.4 significantly enhanced the neutralizing activity, with IC50 of 0.083μg / ml and 0.002μg / ml, respectively, indicating a good synergistic effect ( Fig.18 ).
[0110] Example 13 Pseudovirus system detection of in vitro activity of Nb25.1
[0111] Pseudovirus particles containing VSV-G protein packaged Henipavirus were used to infect suckling mice by in situ injection. Fluorescence signals could be detected in suckling mice 3 days later. After the pseudovirus infected mice in situ, single domain antibodies were injected intraperitoneally. After 3 days, obvious fluorescence elimination effect could be seen ( Figure 19-20 ).
[0112] Example 14 Detection of the Binding Ability of the Single Domain Antibody Fc Fusion Protein Nb25.1-Fc to the G Protein of Hendra Virus
[0113] 200 ng of Hendra virus G protein was coated on an ELISA plate overnight at 4°C, and single-domain antibodies with gradient dilutions were added for incubation. Anti-FLAG-HRP antibody (purchased from SIGMA) was used to detect the binding ability of single-domain antibodies to Hendra virus G protein. The results showed that the Fc fusion protein Nb25.1-Fc of the single-domain antibody had a strong ability to bind to Hendra virus G protein ( Fig.21 ), with an EC50 of 2.418 nM.
[0114] Example 15 Pseudovirus system to detect the neutralizing activity of Nb25.1-Fc and antibody combination
[0115] The G protein-deficient VSV pseudovirus particles carrying the R-luciferase reporter gene were transfected with a plasmid (pMD2.G) containing VSV-G protein, and the supernatant was harvested 72 hours later. The two recombinant plasmids containing the receptor glycoprotein G and fusion protein F on the surface of the henipa virus were co-transfected into 293T cells. After 6 hours, the supernatant infected with VSV-G was added, and then the supernatant was harvested after continuing to culture for 72 hours. The supernatant at this time was the packaged pseudovirus particles of the henipa virus. The antibody was diluted with a cell culture medium containing 10% serum to a final concentration of 200-6.3μg / ml, and then 50μl of the diluted antibody was mixed with 50μl of the virus and added to Huh-7 cells. After culturing at 37°C for 12 hours, fresh culture medium was replaced and cultured for another 48 hours. The relative fluorescence value in the cell lysate was detected using Promega's LuciferaseAssay Kit. The results showed that the single-domain antibody Nb25.1-Fc had a neutralizing effect on the three major Henipaviruses, and its effect was better than that of the single-domain antibody Nb25.1 ( Figure 22-Figure 24 The combination of antibody Nb25.1-Fc and monoclonal antibody m102.4 significantly enhanced the neutralization activity, with IC50 of 0.037μg / ml and 0.002μg / ml, respectively, indicating a good synergistic effect ( Fig.25 ).
[0116] Example 16 Pseudovirus system detection of Nb25.1-Fc in vitro activity
[0117] Pseudovirus particles containing VSV-G protein packaged Henipavirus were used to infect suckling mice by in situ injection. Fluorescence signals could be detected in suckling mice 3 days later. After the pseudovirus infected mice in situ, single domain antibodies were injected intraperitoneally. After 3 days, obvious fluorescence elimination effect could be seen ( Figure 26-Figure 27 ).
[0118] The above description of the disclosed embodiments enables professionals and technicians in the field to implement or use the present invention. The above description is only a preferred embodiment of the present invention. It should be noted that for those skilled in the art, without departing from the principles of the present invention, several improvements and supplements can be made, and these improvements and supplements should also be regarded as the scope of protection of the present invention. Various modifications to these embodiments will be obvious to professionals and technicians in the field, and the general principles defined herein can be implemented in other embodiments without departing from the spirit or scope of the present invention. Therefore, the present invention will not be limited to the embodiments shown herein, but will conform to the widest range consistent with the principles and novel features disclosed herein.
[0119] Sequence Listing
[0120] >SEQ ID NO: 1 (amino acid sequence of Nb25)
[0121] EVQLVESGGGLVQPGGSLRLSCAAS GFTFSSYA MSWVRQAPGKGLEWVSY ISSSSSYT NYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTASYYC ARGLAGVWGIDY WGQGTLVTVSS
[0122] >SEQ ID NO:2 (amino acid sequence of Nb25.1)
[0123] EVQLVESGGGLVQPGGSLRLSCAAS GFTFSSYA MSWVRQAPGKGLEWVSY ISSSSSYT NYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTASYYC ARGLAGVWGIDV WGQGTLVTVSS.
Claims
1. An antibody molecule that binds to a Henipavirus, characterized in that: It comprises an immunoglobulin single variable domain, and the immunoglobulin single variable domain is the sequence shown in SEQ ID NO: 1 or SEQ ID NO:
2.
2. The antibody molecule capable of binding to Henipavirus according to claim 1, characterized in that The immunoglobulin single variable domain comprises an amino acid sequence that is at least 90% identical to any one of the amino acid sequences in SEQ ID NO: 1 and SEQ ID NO:
2.
3. The antibody molecule binding to Henipavirus according to claim 1, characterized in that The immunoglobulin single variable domain comprises an amino acid sequence that is at least 95% identical to any one of the amino acid sequences in SEQ ID NO: 1 and SEQ ID NO:
2.
4. The antibody molecule binding to Henipavirus according to claim 1, characterized in that The immunoglobulin single variable domain comprises an amino acid sequence that is at least 99% identical to any one of the amino acid sequences in SEQ ID NO: 1 and SEQ ID NO:
2.
5. The antibody molecule binding to Henipavirus according to claim 1, characterized in that The immunoglobulin single variable domain is the heavy chain variable region (VH).
6. The antibody molecule binding to Henipavirus according to claim 5, characterized in that The heavy chain variable region (VH) is fully human.
7. The antibody molecule binding to Henipavirus according to any one of claims 1 to 6, which has at least one of the following characteristics: (1) Specific binding to Henipavirus; (2) K binding to the surface receptor glycoprotein G of Henipavirus D Value less than 1×10 -8 M; (3) Can neutralize Henipavirus.
8. A bispecific antibody, characterized in that: A method comprising the antibody molecule according to any one of claims 1 to 7.
9. The bispecific antibody according to claim 8, characterized in that Having at least one of the following characteristics: (1) Specific binding to Henipavirus; (2) K binding to the surface receptor glycoprotein G of Henipavirus D Value less than 1×10 -8 M; (3) Can neutralize Henipavirus.
10. A fusion protein, characterized in that The invention comprises the antibody molecule according to any one of claims 1 to 7, or the bispecific antibody according to any one of claims 8 to 9, and a fusion of a heterologous protein.
11. The fusion protein according to claim 10, characterized in that The heterologous protein is human immunoglobulin Fc.
12. The fusion protein according to claim 10, characterized in that The heterologous protein is human IgG1 Fc.
13. Any fusion protein according to claim 10-12, characterized in that: Having at least one of the following characteristics: (1) Specific binding to Henipavirus; (2) K binding to the surface receptor glycoprotein G of Henipavirus D Value less than 1×10 -8 M; (3) Can neutralize Henipavirus.
14. A conjugate, characterized in that: The antibody molecule according to any one of claims 1 to 7, the bispecific antibody according to any one of claims 8 to 9, or the fusion protein according to any one of claims 10 to 13 is coupled to an effector molecule.
15. The conjugate according to claim 14, characterized in that The effector molecule is a detectable label.
16. The conjugate according to claim 15, characterized in that The detectable label is a fluorescent label, a radioactive label, avidin, biotin, or an enzyme.
17. The conjugate according to any one of claims 14 to 16, characterized in that: Having at least one of the following characteristics: (1) Specific binding to Henipavirus; (2) K binding to the surface receptor glycoprotein G of Henipavirus D Value less than 1×10 8 M; (3) Can neutralize Henipavirus.
18. A nucleic acid molecule characterized in that Encodes the antibody molecule described in claims 1-7.
19. A plasmid, characterized in that Containing the nucleic acid molecule according to claim 18.
20. A host cell, characterized in that Containing the plasmid according to claim 19.
21. A pharmaceutical composition comprising an effective preventive or therapeutic dose of the antibody molecule of any one of claims 1-7, or the bispecific antibody of any one of claims 8-9, or the fusion protein of any one of claims 10-13, or the conjugate of any one of claims 14-17, or the nucleic acid molecule of claim 18, or the plasmid of claim 19, and a pharmaceutically acceptable carrier.
Citation Information
Cited By
Nanometer antibody and multimerization nanometer antibody targeting Nipah virus G protein and application of nanometer antibody and multimerization nanometer antibody
CN117304311A
A nanobody targeting Nipah virus G protein, a polymerized nanobody and its application
CN117304311B
Nipah / Hendea virus recombinant antigen as well as preparation method and application thereof
CN121378498A
Nanobodies to henipavirus and uses thereof
WO2025265116A1
